Introduction to the Organoid Portfolio

Patient-derived tumour Organoids

Organoids are unique self-organising 3D microscopic structures derived from cells that represent a physiologically relevant in vitro model systems as they preserve the genomic, physiological characteristics and multicellularity of the equivalent in vivo tissue.


Explore our Organoid collection

  • Available cancer patient-derived organoids (PDOs) are 3D in vitro multicellular models established from a range of human tumour tissues

  • Represent a novel in vitro platform for basic biological research and potential applications in drug testing and molecular medicine

  • Use in various applications can complement existing experimental models
  • Prof. Motoki Takagi and his group from Fukushima Medical University (FMU) have used an independently developed method to establish F-PDOs

  • Recapitulate characteristics of in vivo tumours

  • Employed protocol does not involve enzyme treatment of the clinical material or use of extracellular matrix – the F-PDOs are cultured in suspension
  • Extensively characterised

  • Comprehensive gene expression, whole-exome sequencing and morphological analyses confirm the F-PDOs retain parental tissue characteristics for extended period of time in culture and after cryopreservation

  • Can be employed prior to using high-cost and time-consuming in vivo models such as patient derived xenografts (PDXs)


Key Features

RLUN21_herceptin only_3h_10bai - with text-2
  • Preserve parental tissue genetic profile and morphology: various characterisation tests confirm F-PDOs retain parental tissue genetic profile and morphology

  • Amenable to extended culture duration: genetically and phenotypically stable for 6 -12 months in culture and after cryopreservation

  • Suspension culture: no extracellular matrix required

  • In  vivo tumorigenesis: suitable for PDX mouse development - gene expression profiles of the xenografts are similar to those of their source F-PDOs and tissues 

  • Suitable for various assays: F-PDOs can be used to establish high-throughput assays to evaluate anticancer agents and antibodies

  • Well-characterized with annotation data: the organoids have been characterised using comprehensive gene expression, whole-exome sequencing and morphological analyses



HubSpot Video
  • Disease modelling 
  • Anticancer agents discovery and development
  • Immuno-oncology assays
  • Compounds’ safety and toxicity testing
  • 3D imaging





Explore our Organoid collection


Back to Blog